Founded in 1995, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. is an innovation-driven pharmaceutical company integrating the R&D, manufacturing, and sales of drugs. As a principal subsidiary of Hansoh Pharma (03692.HK), the Company is committed to improving human health through continuous innovation, focusing on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (“CNS”), metabolism and immunology. The Company has maintained its position for a number of consecutive years in the Top 100 Pharmaceutical Companies in the global market and in the top 3 among China’s Best Industrial Enterprises in the Pharmaceutical R&D Pipeline, and is a key national high-tech enterprise and national technological innovation demonstration enterprise.
With more than 20 years of R&D experience and strong R&D capabilities, the Company has established several state-level R&D platforms, including the National Enterprise Technology Center, Postdoctoral Research Station, and State Key Laboratory. The Company has highly efficient innovative drug discovery capabilities, with R&D efforts covering the fields of peptides, biologics, small molecules, ADC drugs, siRNAs and different modalities related platforms. To date, the Company has undertaken 60 major national science and technology projects, received two Gold Awards of the China Patent Award, and two awards of the National Science and Technology Progress Award. Hansoh has been granted more than 600 invention patents both domestically and internationally, and has participated in formulating over 200 national pharmaceutical standards.
Jiangsu Hansoh Pharma has so far marketed 7 innovative drugs, and has more than 70 clinical trials of innovative drug candidates being investigated, covering more than 40 innovative drug candidates, forming a competitive pipeline. Our innovative drugs on the market include: Saint Luolai (Pegmolesatide Injection), the only class 1 small molecule peptide chemical drug approved for marketing worldwide in the field of renal anaemia treatment; Ameile (Aumolertinib mesylate tablets), the first original third-generation EGFR-TKI innovative drug in China; The first China-originated EGFR-TKI approved overseas; XINYUE (Inebilizumab injection), the first CD19-targeted monoclonal antibody approved in China; Hengmu (Tenofovir amibufenamide tablets), the first wholly developed oral dose medicine indicated for the treatment of hepatitis B virus (HBV) infection in China; Hansoh Xinfu (Flumatinib mesylate tablets), the first original second-generation TKI for chronic myelogenous leukemia in China; Fulaimei (PEG-loxenatide for injection), tirst original GLP-1RA weekly formulation in China; and Mailingda (Morinidazole sodium chloride injection), the world's first nitroimidazole anti-anaerobic innovative drug over the past 40 years. Eleven indications of these innovative drugs have been included in the National Reimbursement Drug List. In 2025, the proportion of revenue from innovative drugs and cooperative products in total revenue increased to 82.2%, and Jiangsu Hansoh Pharma has successfully transformed into an innovative biopharmaceutical company.
Jiangsu Hansoh Pharma has always maintained dynamic consistency with global advanced access levels by continuously designing and building production facilities and production lines in accordance with international advanced standards and using advanced production equipment. Our production quality system has been officially certified by FDA in the United States, EMA of the European Union, and PMDA in Japan, and finished preparations and APIs have been approved for marketing in Europe, America, Japan, etc.
Looking ahead, Jiangsu Hansoh Pharma will further deepen its innovation-driven strategy, targeting the unmet clinical needs of Chinese and international patients, and develop more innovative drugs to improve the quality of human life.
